Trastuzumab duocarmazine

DB16342Investigational

Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Also known as: Immunoglobulin g1-kappa, anti-(homo sapiens erbb2 (epidermal growth factor receptor 2, receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibody conjugated to the pro-drug seco-duocarmycinhydroxyb
Code names: SYD-985

Resolves to

Compound

UNIIXCR2BZ80N7CAS1642152-40-6

Clinical / RWD

ATCL01FD05

Targets

P04626ERBB2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 14 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Trastuzumab duocarmazine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account